Show simple item record

dc.contributor.authorBrowning, Michael
dc.date.accessioned2021-01-05T18:37:30Z
dc.date.available2021-01-05T18:37:30Z
dc.date.issued2017-02
dc.identifier.citationBrowning, M., 2017. Symptom trajectories in discontinuation trials. Lancet Psychiatry 4, 176–178en
dc.identifier.issn2215-0366
dc.identifier.urihttps://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/702
dc.description.abstractMany patients with clinical depression, particularly those with recurrent illness, are treated with maintenance antidepressants after an acute-phase response. But how effective is this approach? The effectiveness of maintenance treatment is most commonly tested in trials with a discontinuation design, 1 in which patients who have already responded to a treatment are randomly assigned to either ongoing treatment or placebo. Such studies provide a measure of the benefit of maintenance treatment over discontinuation. However, discontinuation studies have several limitations. The first is common to psychiatric treatment studies generally; how and when should we assess whether a patient's symptoms have changed after discontinuation? The second is more specific to discontinuation designs; the selection of patients based on a positive response to that treatment is likely to inflate the apparent beneficial effect of the treatment, because that subgroup of patients has the most to lose from stopping treatment.en
dc.description.urihttps://doi.org/10.1016/S2215-0366(17)30054-8en
dc.language.isoenen
dc.subjectDepressive Disordersen
dc.subjectAntidepressant Drugsen
dc.titleSymptom trajectories in discontinuation trials.en
dc.typeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record